Interventions Aimed at Decreasing Obesity in Hispanic Children in the First 1000 Days: A Systematic Review

Ahmed Ismaeel1,2, Suzy Weems3, Megan McClendon4

  • 1Nutrition Sciences, Family and Consumer Sciences, Baylor University, One Bear Place #97346, Waco, TX, 76798, USA. Ahmed_Ismaeel@baylor.edu.

Insights

Interventions targeting obesity in Hispanic children during the first 1000 days of life show promise. Four of five studies reported improvements, though research quality and quantity are limited.

Area of Science:

  • Pediatrics
  • Public Health
  • Nutrition Science

Background:

  • Obesity prevalence is disproportionately high among Hispanic children.
  • Addressing this disparity is a critical public health concern.
  • Early life interventions (first 1000 days) are crucial for long-term health.

Purpose of the Study:

  • To review and assess the effectiveness of interventions aimed at reducing obesity in Hispanic children within their first 1000 days.
  • To identify successful intervention strategies and highlight research gaps.

Main Methods:

  • Comprehensive literature search of MEDLINE, Scopus, and PubMed.
  • Inclusion of studies evaluating obesity prevention/reduction interventions for Hispanic infants and toddlers.
  • Quality assessment using the GRADE system.

Main Results:

  • Five studies met inclusion criteria; only one was high quality.
  • Three lifestyle and two educational interventions were identified.
  • Four of the five interventions demonstrated significant improvements in outcome measures.
  • Limited research exists for the 0-2 year age group.

Conclusions:

  • Evidence suggests early life interventions can positively influence obesity-related behaviors in Hispanic children.
  • Future research should focus on high-quality studies with clinical obesity measures.
  • Successful intervention themes should be incorporated into future designs.

Related Concept Videos

Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.4K
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
279
Community Based Intervention01:30

Community Based Intervention

Community-based interventions in mental health represent a paradigm shift from institution-centered care to treatments embedded within the fabric of local communities. By prioritizing inclusion and leveraging existing societal structures, this approach fosters a supportive environment conducive to addressing mental health challenges while promoting individual dignity and agency.
Foundations of Community Mental Health Programs
Central to the success of community-based interventions is the...
496
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
344
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
199
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
302